GlassScriptPhysician profile
Manish R Patel
NPI 1457408254
$122,677.53
in general payments reported to CMS, 2019-2025
100 companies · $22K in 2025
The $22K reported for 2025 was more than what 89% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $4,671 · 2021: $23K · 2022: $16K · 2023: $15K · 2024: $22K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $25K · Consulting Fee: $12K · Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,884 · Education: $3,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $24,736.45 |
| Consulting Fee | $12,265.00 |
| Food and Beverage | $11,741.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,884.29 |
| Education | $3,402.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $28,847.50 | 2020-2025 | Enhertu, Datroway |
| Boehringer Ingelheim International Gmbh | $23,088.12 | 2019-2024 | |
| Emd Serono, INC. | $9,050.52 | 2019-2025 | Bavencio |
| Intrinsiq Specialty Solutions, INC. | $8,437.50 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $7,886.03 | 2019-2025 | Opdivo, Opdualag |
| Janssen Global Services, LLC | $6,500.00 | 2022 | |
| F. Hoffmann-La Roche Ag | $4,049.10 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $3,511.35 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Tanabe Pharma America, INC. | $2,940.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,239.62 | 2019-2025 | Gilotrif |
| Ipsen Biopharmaceuticals, INC | $2,206.39 | 2022-2025 | Onivyde |
| Adaptive Biotechnologies Corporation | $2,096.03 | 2019-2025 | Clonoseq |
| Janssen Biotech, INC. | $2,035.53 | 2019-2025 | Darzalex, Rybrevant, Tecvayli |
| Bayer Healthcare Pharmaceuticals INC. | $1,766.95 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,451.57 | 2019-2025 | Enhertu, Imfinzi, Calquence |
Show all 97 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $1,400.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $1,107.45 | 2019-2025 | |
| Lilly USA, LLC | $1,078.88 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $1,077.35 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Pfizer INC. | $994.79 | 2019-2025 | |
| Boehringer Ingelheim Pharma Gmbh & Co.Kg | $820.88 | 2020 | |
| Incyte Corporation | $820.24 | 2020-2025 | Jakafi, Monjuvi |
| Array Biopharma INC | $577.31 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Seagen INC. | $527.01 | 2020-2023 | Adcetris, Padcev, Tukysa |
| Genzyme Corporation | $518.99 | 2019-2024 | |
| Gilead Sciences, INC. | $514.44 | 2019-2025 | Trodelvy |
| Eisai INC. | $430.52 | 2020-2025 | |
| Amgen INC. | $384.24 | 2019-2022 | |
| Depuy Synthes Sales INC. | $351.74 | 2019-2023 | Attune |
| Astellas Pharma US INC | $342.58 | 2019-2025 | Xtandi, Padcev, Xospata |
| Glaxosmithkline, LLC. | $319.39 | 2020-2025 | Ojjaara, Shingrix, Blenrep |
| Genentech USA, INC. | $289.62 | 2019-2025 | Tecentriq, Alecensa, Rozlytrek |
| Puma Biotechnology, INC. | $277.27 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $266.46 | 2021-2025 | Fruzaqla, Ninlaro, Vonvendi |
| Jazz Pharmaceuticals INC. | $262.59 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $239.90 | 2019-2025 | Libtayo |
| Abbvie INC. | $239.37 | 2021-2025 | |
| Kite Pharma, INC. | $210.05 | 2020-2023 | Yescarta |
| Beigene USA, INC. | $207.01 | 2020-2024 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $204.41 | 2020-2025 | Rezlidhia, Tavalisse, Gavreto |
| Alexion Pharmaceuticals, INC. | $187.31 | 2021-2025 | Ultomiris |
| Sobi, INC | $185.53 | 2022-2025 | |
| Beone Medicines USA, INC. | $153.25 | 2025 | Brukinsa, Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $146.45 | 2020-2023 | Imbruvica, Epkinly |
| Stemline Therapeutics INC. | $131.17 | 2023-2025 | Orserdu |
| Geron Corporation | $116.22 | 2025 | Rytelo |
| Epizyme, INC. | $115.84 | 2022-2024 | Tazverik, Onivyde |
| Exelixis INC. | $111.95 | 2019-2023 | Cabometyx |
| Sumitomo Pharma America, INC. | $103.07 | 2023-2025 | Orgovyx |
| Foundation Medicine, INC. | $93.15 | 2021-2022 | |
| Cti Biopharma Corp. | $92.93 | 2022-2023 | Vonjo |
| Janssen Pharmaceuticals, INC | $84.45 | 2019-2021 | |
| Mirati Therapeutics, INC. | $81.53 | 2023-2024 | Krazati |
| Deciphera Pharmaceuticals INC. | $79.92 | 2020-2022 | |
| Morphosys, US INC. | $67.07 | 2023 | Monjuvi |
| Adc Therapeutics America, INC. | $66.27 | 2022-2025 | |
| Servier Pharmaceuticals LLC | $62.02 | 2021-2024 | |
| Syndax Pharmaceuticals, INC. | $61.26 | 2025 | |
| Kyowa Kirin, INC. | $61.02 | 2021-2023 | Poteligeo |
| Taiho Oncology, INC. | $60.09 | 2021-2025 | |
| Acrotech Biopharma INC. | $57.01 | 2021-2024 | Beleodaq |
| Modernatx, INC. | $56.00 | 2023 | |
| Blueprint Medicines Corporation | $55.54 | 2023-2024 | Ayvakit |
| Aveo Pharmaceuticals, INC. | $52.13 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $48.71 | 2023-2025 | Monoferric |
| Karyopharm Therapeutics INC. | $46.13 | 2020-2023 | Xpovio |
| Dendreon Pharmaceuticals LLC | $45.19 | 2025 | Provenge |
| Dova Pharmaceuticals | $39.39 | 2021 | |
| Genentech, INC. | $38.48 | 2023 | Rozlytrek, Avastin, Gavreto |
| Tersera Therapeutics LLC | $34.69 | 2019-2022 | |
| Agios Pharmaceuticals, INC. | $32.08 | 2021-2024 | Pyrukynd |
| Springworks Therapeutics, INC. | $31.52 | 2024 | Ogsiveo |
| Alnylam Pharmaceuticals INC. | $31.29 | 2022-2023 | Givlaari |
| Iovance Biotherapeutics, INC. | $31.12 | 2025 | Amtagvi |
| Tg Therapeutics, INC. | $29.54 | 2021-2022 | |
| Tesaro, INC. | $29.39 | 2019 | |
| Gt Medical Technologies, INC | $29.11 | 2022 | |
| Clovis Oncology, INC. | $28.38 | 2019-2020 | |
| Helsinn Therapeutics (U.S.), INC. | $27.47 | 2019 | |
| Sun Pharmaceutical Industries INC. | $24.54 | 2020 | |
| Myovant Sciences INC. | $24.14 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $23.34 | 2025 | Empaveli |
| Heron Therapeutics, INC. | $22.67 | 2019 | |
| Recordati_rare_diseases_inc. | $21.38 | 2023 | Panhematin |
| Genmab U.S., INC. | $17.90 | 2025 | Epkinly |
| Pharmaessentia USA Corporation | $16.67 | 2023 | Besremi |
| Sirtex Medical INC | $16.59 | 2019 | |
| Menarini Silicon Biosystems, INC. | $16.51 | 2025 | |
| Legend Biotech USA INC. | $16.12 | 2024 | |
| Ge Healthcare | $15.58 | 2021 | |
| Partner Therapeutics, INC. | $15.00 | 2019 | |
| Immunomedics, INC. | $14.10 | 2020 | |
| Novocure INC. | $14.03 | 2025 | Optune Lua (Novottf-200t) |
| Lexicon Pharmaceuticals, INC. | $12.84 | 2020 | |
| Boston Scientific Corporation | $11.98 | 2022 | |
| Aurobindo Pharma USA, INC. | $10.97 | 2019 | |
| Shire North American Group INC | $10.80 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$15,865.88 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.